Idelalisib-d5

• CAT Number: S000166
• CAS Number: 1830330-31-8
• Molecular Formula: C22H13D5FN7O
• Molecular Weight: 420.45
• Purity: ≥95%
• Target: Autophagy
• IUPAC Name: 5-fluoro-3-(2,3,4,5,6-pentadeuteriophenyl)-2-[(1S)-1-(7H-purin-6-ylamino)propyl]quinazolin-4-one
• InChI: InChI=1S/C22H18FN7O/c1-2-15(28-20-18-19(25-11-24-18)26-12-27-20)21-29-16-10-6-9-14(23)17(16)22(31)30(21)13-7-4-3-5-8-13/h3-12,15H,2H2,1H3,(H2,24,25,26,27,28)/t15-/m0/s1/i3D,4D,5D,7D,8D
• InChIKey: IFSDAJWBUCMOAH-LPJONKDZSA-N
• SMILES: [2H]C1=C(C(=C(C(=C1[2H])[2H])N2C(=O)C3=C(C=CC=C3F)N=C2[C@H](CC)NC4=NC=NC5=C4NC=N5)[2H])[2H]

Idelalisib-d5 (CAS: 1830330-31-8), a premium pharmaceutical research compound designed for advanced oncology and immunotherapy studies. As a deuterated analog of Idelalisib, it offers enhanced stability and improved pharmacokinetic properties. Idelalisib-d5 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for cancer and autoimmune diseases. Trusted by leading laboratories, Idelalisib-d5 is your go-to solution for cutting-edge cancer and immunology research. Unlock new possibilities in treatment with Idelalisib-d5, where innovation meets reliability.

Reference

[1]. Lannutti BJ, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood, 2011, 117(2), 591-594.
[Content Brief]